![](https://academy.idsociety.org/sites/default/files/styles/course_image/public/AS%20Curriculum%20course%20header%20self%20study%20square.png?itok=leNHAVBL)
Section 1: Introduction to Antimicrobial Stewardship (Self Study for medical students)
Congratulations!
You now have access to the 2019 Core Antimicrobial Stewardship (CAS) Curriculum Self Study.
Start by reviewing the Self Study User Guide to get familiar with background information and concepts that will be presented during this course.
Next, download the following resources below.
- Self Study Roadmap/User Guide - full resource manual that explains the overall curriculum, learning objectives, and navigating the LMS
- Curriculum Planner - one page document that allows you to build a timeline for completing all sections and modules
- AS Clinical Teaching Tool - front/back document used to apply and reinforce AS principles into everyday clinical practice
- AS Core Concepts - one page document that covers the 5 Core Concepts for the Curriculum
Be sure to complete the Self Study Pre and Post Curriculum Survey. They are required in order to receive CME/MOC credit and your certificate.
Target Audience
Infectious Diseases Professionals who desire to learn more about antimicrobial stewardship but are not in a participating fellowship program, no longer in fellowship, or would like to gain more knowledge on the subject.
Learning Objectives
Upon completion of Section 1, you should be able to:
- Define antimicrobial stewardship, its programmatic goals, and key strategies to achieve the goals
- Relate trends and patterns between antimicrobial use and resistance
- Recognize adverse events associated with the use of specific antimicrobials, including the risk for development of C. difficile infections
- Describe the role of clinical and laboratory diagnostic tools in improving antimicrobial use
- Define expected outcomes of an ASP
NOTE: Because this curriculum was initially designed specifically for fellows, you may hear repeated reference to "fellows" ,"stewards in training" or "fellows/trainees"
Additional Information
Attachment | Size |
---|---|
![]() | 121.44 KB |
![]() | 146.95 KB |
![]() | 240.33 KB |
![]() | 565.36 KB |
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found
Name | Individual's Role in Activity | Name of Commercial Interest | Nature of Relationship |
---|---|---|---|
Abbo, Lillian | Workgroup member | Pfizer Brazil | Honoraria |
Advani, Sonali | Workgroup member | Nabriva Therapeutics | Advisory/Consultant Role |
Amstrong, Wendy | Workgroup member | None | |
Barsoumian, Alice | Workgroup member | None | |
Beeler, Cole | Workgroup member | None | |
Bystritsky, Rachel | Workgroup member | None | |
Cherabuddi, Kartik | Workgroup member | Gatorade | Start - up Research Fund |
NIH (Medimmune) | Research Grant | ||
Cohen, Seth | Workgroup member | None | |
Hamilton, Keith | Workgroup member | None | |
Ince, Dilek | Workgroup member | Ansun Pharma | Research Grant |
Justo, Julie Ann | Workgroup member | None | |
Logan, Ashleigh | Staff | None | |
Luther, Vera | Workgroup member | None | |
Lynch, John | Workgroup member | Astellas Pharmaceuticals, Juno Therapeutics | Advisory/Consultant Role |
Nori, Priya | Workgroup member | None | |
Ohl, Christopher | Workgroup member | Paratek, Bayer, Cempra Pharmaceuticals | Advisory/Consultant Role |
Patel, Payal | Workgroup member | None | |
Pottinger, Paul | Workgroup member | McGraw Hill, Elsevier | Honoraria |
Schwartz, Brian | Workgroup member | None | |
Spicer, Jennifer | Workgroup member | None | |
Stack, Conor | Workgroup member | None | |
Zhou, Yuan | Workgroup member | None | |
Shnekendorf, Rachel | Staff | None |